Concepedia

James M. Youakim

JM

20

Publications

1.4K

Citations

17

H-Index

1998

Active since

Affiliations

Acadia Pharmaceuticals (United States)(Current)

Vanderbilt University Medical Center

Texas Children's Hospital

University of Alabama at Birmingham

University of Colorado Denver

James M. Youakim is an author at Acadia Pharmaceuticals (United States) specializing in medicine, psychiatry, and sleep.

ORCID

Top concepts

Publications per year

1998–2024

20

Publications

20

Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study

Clive Ballard, Carol Banister, Zunera Khan et al. · The Lancet Neurology · 2018 · 187 citations

, , +11

Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study

Jeffrey L. Neul, Alan K. Percy, Tim A. Benke et al. · Nature Medicine · 2023 · 173 citations · Full text

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder

Michael E. Thase, James M. Youakim, Aleksandar Skuban et al. · The Journal of Clinical Psychiatry · 2015 · 171 citations

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants

Michael E. Thase, James M. Youakim, Aleksandar Skuban et al. · The Journal of Clinical Psychiatry · 2015 · 160 citations

Trial of Pimavanserin in Dementia-Related Psychosis

Pierre N. Tariot, Jeffrey L. Cummings, Maria Soto‐Martin et al. · New England Journal of Medicine · 2021 · 127 citations · Full text

Rows per page

1–5 of 20